News

KARO PHARMA ANNOUNCES AGREEMENT WITH THE AUSTRIAN PHARMACEUTICAL COMPANY MARINOMED BIOTECH AG

27 November, 2017

· Karo Pharma AB and the Austrian pharmaceutical company Marinomed Biotech AG today announced a license agreement under which Karo Pharma will market a patented product for common cold & flu symptoms in Sweden, Norway and Finland. · The product is very well documented with 4 clinical trials in which more than 650 adults and...

Läs mer

COMPULSORY ACQUISITION OF SHARES IN WEIFA ASA

12 October, 2017

· Reference is made to the stock exchange announcement made by Karo Pharma AB (“Karo Pharma”) on 6 October 2017 regarding completion of the voluntary offer (the “Voluntary Offer”) for the shares in Weifa ASA (“Weifa”). · Karo Pharma currently owns 35,553,352 shares in Weifa representing 97.48 % of Weifa’s share capital and voting rights....

Läs mer

KARO PHARMA AB COMPLETES VOLUNTARY OFFER FOR WEIFA ASA

06 October, 2017

· Karo Pharma AB (“Karo Pharma”) has today successfully completed the voluntary offer for Weifa ASA (“Weifa”). Payment of the offer price is being made today to the Weifa shareholders who accepted the voluntary offer and the cash consideration will be available on such shareholders’ registered bank accounts in the VPS on or around 9...

Läs mer

FINAL RESULT OF THE VOLUNTARY OFFER FOR WEIFA ASA

05 October, 2017

· Following final registration of acceptances, the final acceptance level in Karo Pharma AB’s (“Karo Pharma”) voluntary offer (“Voluntary Offer”) to acquire all shares in Weifa ASA (“Weifa”) is 35,463,139 shares representing 97.23% of the total shares in Weifa on a fully diluted basis.   · It is expected that the settlement of the Voluntary...

Läs mer

EXPIRATION OF VOLUNTARY OFFER PERIOD FOR WEIFA ASA – ACQUISITION SUCCESSFUL WITH ACCEPTANCES AT +97,1 %

03 October, 2017

· On expiration of the offer period on 3 October, 2017 at 16:30 CEST, Karo Pharma AB (“Karo Pharma”) had received acceptances for the voluntary offer (“Voluntary Offer”) to acquire all shares in Weifa ASA (“Weifa”) for a total of 35 414 529 shares representing approximately 97,1 % of the total shares in Weifa on a fully...

Läs mer

UPDATE ON VOLUNTARY OFFER FOR ACQUISITION OF WEIFA ASA – ACCEPTANCES AT +90,3%

28 September, 2017

STOCKHOLM 28 september 2017 · As of today Karo Pharma has received acceptances under the Voluntary Offer for a total of 32 949 919 shares representing at +90,3% of the total shares in Weifa on a fully diluted basis. Accordingly, the conditions for completion of the Voluntary Offer have now been met.  · The offer...

Läs mer

Extends the offer period for the voluntary offer to acquire weifa

26 September, 2017

· Karo Pharma AB has decided that the previously announced voluntary cash offer to acquire Weifa ASA will be extended by one week to 3 October 2017 at 16.30 (CEST) · As of today Karo Pharma has received acceptances under the Voluntary Offer for a total of 32 294 687 shares representing approximately 88.55 %...

Läs mer

COMMENCES VOLUNTARY CASH OFFER TO ACQUIRE WEIFA

11 September, 2017

· Karo Pharma AB commences the previously announced voluntary cash offer to acquire Weifa ASA following the approval of the Offer document to the shareholders in Weifa ASA by the Oslo Stock Exchange (OSE). · The Offer document, containing the complete terms and conditions of the Offer will be distributed to all shareholders listed in...

Läs mer

Karo Pharma AB announces a recommended voluntary cash offer to acquire all shares in Weifa ASA

24 August, 2017

· Cash offer at NOK 35 per Weifa share valuing the total share capital of Weifa at approximately NOK 1.28 billion on a fully diluted basis · Recommended by the Board of Directors of Weifa · Pre-acceptances of the Offer from shareholders together representing approximately 45.35% of the issued share capital of Weifa and purchase...

Läs mer

Annual General Meeting 2017 in Karo Pharma AB (publ)

11 May, 2017

STOCKHOLM, Sweden, May 11, 2017 – At today’s Annual General Meeting in Karo Pharma the following main resolutions were passed. The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company. The AGM decided that funds at the disposal of the general meeting, amounting to SEK...

Läs mer

Karo Pharma - Pfizer Collaboration reaches second milestone

04 May, 2017

Karo Pharma has received a milestone for the RORgamma project amounting to 2 million USD. “This is the second milestone-payment for RORgamma. Very good news for the project” says Anders Lönner, Chairman of the Board. For further information, please contact: Henrik Palm, CFO, Telephone +46 70 540 40 14 or E-mail henrik.palm@karopharma.se The information in...

Läs mer

NOTICE OF ANNUAL GENERAL MEETING IN KARO PHARMA AB

10 April, 2017

Right to attend  Entitled to attend the annual general meeting are those who are both registered shareholders in the share register held by Euroclear Sweden AB at the record date May 5, 2017 and have notified the company of their intention to attend the general meeting no later than on May 5, 2017. Shareholders with...

Läs mer

Change of the number of shares and votes in Karo Pharma

28 February, 2017

STOCKHOLM, February 28, 2017 – Karo Pharma AB today announces that the company´s total number of shares as per February 28, 2017 amount to 82,166,391 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the recently completed share issue of 18,259,198 shares. The issue was...

Läs mer